R2R01 / River 2 Renal - LARVOL DELTA

R2R01-CSA-AKI-201: A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated - Acute Kidney Injury. (clinicaltrialsregister.eu) - P1/2 | N=440 | Not yet recruiting | Sponsor: River 2 Renal Corp.

New P1/2 trial • Acute Kidney Injury • Cardiovascular • Nephrology • Renal Disease

R2R01-CSA-AKI-201: A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated - Acute Kidney Injury. (clinicaltrialsregister.eu) - P1/2 | N=390 | Not yet recruiting | Sponsor: River 2 Renal Corp.

New P1/2 trial • Acute Kidney Injury • Cardiovascular • Nephrology • Renal Disease

Optimization of Single Relaxin B-Chain Peptide Leads to the Identification of R2R01, a Potent, Long-Acting RXFP1 Agonist for Cardiovascular and Renal Diseases. (PubMed, J Med Chem) - "Compound 21 (R2R01) was then selected as a candidate for an in-depth characterization. It is currently undergoing phase 2 clinical development for renal and cardiovascular diseases."

Journal • Cardiovascular • Nephrology • Renal Disease

R2R01-WHF-201: To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF) (clinicaltrials.gov) - P2 | N=33 | Completed | Sponsor: River 2 Renal Corp. | Recruiting ➔ Completed | Trial completion date: Mar 2025 ➔ Nov 2024

Trial completion • Trial completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

R2R01-WHF-201: To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF) (clinicaltrials.gov) - P2 | N=32 | Recruiting | Sponsor: River 2 Renal Corp. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

R2R01: A long-acting single-chain peptide agonist of RXFP1 for renal and cardiovascular diseases. (PubMed, Br J Pharmacol) - "R2R01 is a potent RXFP1 agonist with an extended half-life that increases renal blood flow in various settings including normotensive and hypertensive conditions. The preclinical efficacy and safety data supported clinical development of R2R01 as a potential new therapy for renal and cardiovascular diseases."

Journal • Allergy • Cardiovascular • Congestive Heart Failure • Heart Failure • Nephrology • Renal Disease • CD4

R2R01-WHF-201: To Evaluate the Safety, Tolerability and Efficacy of R2R01 Combined With SOC as Compared to SOC Alone in Outpatients With Worsening Heart Failure (WHF) (clinicaltrials.gov) - P2 | N=32 | Not yet recruiting | Sponsor: River 2 Renal Corp.

New P2 trial • Cardiovascular • Congestive Heart Failure • Heart Failure